We’d like to invite you to Codetta Bio’s upcoming webinar focused on the recent advancements in immunoassay technology brought to you by their Technology Access Program (TAP).

Existing technologies in today’s biomarker analysis market face challenges that relate to clinicians and researchers alike, requiring multiple instruments, multiple workflows, multiple samples, and multiple labs which all lead to a complicated, timely, and costly process that ends up providing disparate datasets that are difficult to analyze.

During this webinar, the Codetta team will share how they are shifting this technology paradigm, and more specifically, how their innovative immunoassay panel delivers high-value immunomodulatory proteins with ultra-sensitive detection—a capability that sets a new standard in the market.

At the heart of their offering is the Codetta platform, which revolutionizes multiplexing with an impressive dynamic range of up to 108 from a single sample. This unparalleled capability is powered by their unique trifecta which entails:

 Digital PCR Methods – Allowing for the detection of low target proteins with exceptional precision.

 Analog Quantification (qPCR) – Enabling accurate quantification of high target concentrations.

 and Noise-Canceling Technology – A proprietary feature that eliminates background signals, addressing another common challenge found in today's multiplex assays.

The Codetta platform stands out in the market by offering unmatched value through several key features which include:

Digital ELISA Sensitivity – Achieving new levels of sensitivity in protein detection.

Increased Multiplexing Capability – Allowing for more comprehensive and simultaneous analysis.

Reduced Assay Cross-Talk – Ensuring the integrity and accuracy of results by minimizing interference between assays.

Flexible Workflow and Panel Design – Adapting seamlessly to various research needs and environments.

In this webinar, the team will delve into the innovative features and benefits of the Codetta platform and discuss how you can participate in their Technology Access Program (TAP). TAP is an exclusive, early access scheme that allows participants to experience this cutting-edge technology firsthand. By joining TAP, you’ll gain early access to the Codetta platform, participate in pilot projects, and provide feedback that will shape the future of immunoassay technology.

We invite you to listen in as Jacques Corriveau, CEO; Jeremy Lambert, VP of Product Management; and Adrian Arechiga, VP of Marketing discuss how the Codetta Bio platform is poised to transform immunoassay technology, providing researchers and clinicians with tools that offer unprecedented sensitivity, flexibility, and efficiency.

See you July 11th at 11 am ET!